Could a common diabetes drug improve dialysis outcomes?

NCT ID NCT07491042

Recruiting now Disease control Sponsor: Oman Ministry of Health Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether dapagliflozin, a drug usually used for diabetes, can help people with end-stage kidney disease who are on peritoneal dialysis. Over six months, 38 participants will take the drug daily to see if it improves fluid removal, dialysis adequacy, and urine output. The goal is to find a new way to enhance dialysis effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin (SGLT2 inhibitor)
What this could lead to: If it works, this could point toward a way to improve fluid removal and dialysis adequacy in patients on peritoneal dialysis.
What could go wrong: This is a small, early-phase trial with only 38 participants and no control group, so results may not be conclusive. Risks include urinary tract infections and hypoglycemia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE CHRONIC RENAL FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END STAGE CHRONIC RENAL FAILURE

Contacts and locations

Locations

Jehad Badawi AL LAHAM
RECRUITING

Nizwa, Oman

More trials for these conditions

Other studies related to the condition(s) this trial covers.